

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM409593

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BioCryst Pharmaceuticals, Inc.		12/05/2016	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Seqirus UK Limited		
Street Address:	100 New Bridge Street		
City:	London		
State/Country:	UNITED KINGDOM		
Postal Code:	EC4V		
Entity Type:	Corporation: UNITED KINGDOM		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	4778059	RAPIVAB	
CORRESPONDENCE DATA			
Fax Number:	2054886267		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	205-521-8267		
Email:	devans@bradley.com		
Correspondent Name:	Donita Evans		
Address Line 1:	1819 Fifth Avenue North		
Address Line 2:	Bradley		
Address Line 4:	Birmingham, ALABAMA 35203		
NAME OF SUBMITTER:	Donita Evans		
SIGNATURE:	/donita evans/		
DATE SIGNED:	12/20/2016		
Total Attachments: 4			
source=Rapivabassign#page1.tif			
source=Rapivabassign#page2.tif			
source=Rapivabassign#page3.tif			
source=Rapivabassign#page4.tif			

OP \$40.00 4778059



DAVIES COLLISON CAVE

BETWEEN

BioCryst Pharmaceuticals, Inc.

AND

Seqirus UK Limited

**CONFIRMATORY DEED OF ASSIGNMENT
- UNITED STATES OF AMERICA -**

DAVIES COLLISON CAVE
Patent & Trade Mark Attorneys
1 Nicholson Street
Melbourne Victoria 3000
Australia

TRADEMARK
REEL: 005940 FRAME: 0158

**CONFIRMATORY DEED OF ASSIGNMENT
(USA)**

THIS DEED is made the 5th day of December 2016

BETWEEN: **BioCryst Pharmaceuticals, Inc.** of 2190 Parkway Lake Drive,
Birmingham Alabama 35244, United States of America ("the Assignor")

AND: **Seqirus UK Limited** of 100 New Bridge Street, London, England EC4V
6JA, United Kingdom ("the Assignee")

WHEREAS:


- A. The Assignor is the owner of United States of America trade mark registration no. 4778059, details of which are set out in Schedule 1 ("the Trade Mark").
- B. Pursuant to an Agreement between the Assignor and the Assignee dated 16 June 2015 ("the Agreement"), the Assignor transferred ownership of all right, title and interest in the Trade Mark to the Assignee including all such right, title and interest as the Assignor has in the goodwill of the business concerned in the goods and services in respect of which the Trade Mark is registered.

NOW THIS DEED WITNESSETH:

- 1. That for good and valuable consideration and pursuant to the Agreement, the Assignor has assigned all such right, title and interest as the Assignor had in and to the Trade Mark together with such right, title and interest the Assignor has in the goodwill of the business concerned in the goods and services in respect of which the Trade Mark is registered, to the Assignee absolutely.
- 2. This Deed may be executed in any number of counterparts, and by the parties on separate counterparts. Each counter part shall constitute an original of this Deed, but all the counterparts shall together constitute one and the same Deed.

IN WITNESS WHEREOF the parties have executed this Deed the day and year first hereinbefore written.


Executed by the authority of, for
and on behalf of **BioCryst
Pharmaceuticals, Inc.**




.....
Signature

ALANE BARNES
.....
Name (BLOCK CAPITALS)
VP, GENERAL COUNSEL
.....
Position within
BioCryst Pharmaceuticals, Inc.

Executed by the authority of, for
and on behalf of **Seqirus UK
Limited** by



.....
Signature
NICOLE RIZZO SMITH
.....
Name (BLOCK CAPITALS)
Authorized Representative
.....
Position within
Seqirus UK Limited



.....
Signature of Witness

Schedule 1

Mark	Number	Filing Date	Class	Status
RAPIVAB	4778059	12 December 2013	5	Registered